These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2657749)

  • 21. Prediction of pH-dependent aqueous solubility of druglike molecules.
    Hansen NT; Kouskoumvekaki I; Jørgensen FS; Brunak S; Jónsdóttir SO
    J Chem Inf Model; 2006; 46(6):2601-9. PubMed ID: 17125200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboxamide-pyridine N-oxide heterosynthon for crystal engineering and pharmaceutical cocrystals.
    Reddy LS; Babu NJ; Nangia A
    Chem Commun (Camb); 2006 Apr; (13):1369-71. PubMed ID: 16550269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselectivity of binding of alpha-(N-benzylamino)benzylphosphonic acids to prostatic acid phosphatase.
    Vovk AI; Mischenko IM; Tanchuk VY; Kachkovskii GA; Sheiko SY; Kolodyazhnyi OI; Kukhar VP
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4620-3. PubMed ID: 18672366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prodrug strategies to overcome poor water solubility.
    Stella VJ; Nti-Addae KW
    Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A material science perspective of pharmaceutical solids.
    Cui Y
    Int J Pharm; 2007 Jul; 339(1-2):3-18. PubMed ID: 17537600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
    Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ
    Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular conceptor for training in medicinal chemistry, drug design, and cheminformatics.
    Cohen C; Fischel O; Cohen E
    Chem Biol Drug Des; 2007 Jan; 69(1):75-82. PubMed ID: 17313460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of chemical double-mutant cycles in biomolecular recognition studies: application to HCV NS3 protease inhibitors.
    Kawai SH; Bailey MD; Halmos T; Forgione P; Laplante SR; Llinàs-Brunet M; Naud J; Goudreau N
    ChemMedChem; 2008 Nov; 3(11):1654-7. PubMed ID: 18942693
    [No Abstract]   [Full Text] [Related]  

  • 30. Tetraplex DNA specific ligands based on the fluorenone-carboxamide scaffold.
    Alcaro S; Artese A; Iley JN; Maccari R; Missailidis S; Ortuso F; Ottanà R; Ragazzon P; Vigorita MG
    Bioorg Med Chem Lett; 2007 May; 17(9):2509-14. PubMed ID: 17317164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Val 216 in class A beta-lactamases with tricyclic 6-methylidene penems.
    Venkatesan A; Agarwal A; Abe T; Ushirogochi H; Takasaki T; Mihira A; Mansour TS
    ChemMedChem; 2008 Nov; 3(11):1658-61. PubMed ID: 18924212
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
    Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
    J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The identification of potent, selective, and bioavailable cathepsin S inhibitors.
    Gauthier JY; Black WC; Courchesne I; Cromlish W; Desmarais S; Houle R; Lamontagne S; Li CS; Massé F; McKay DJ; Ouellet M; Robichaud J; Truchon JF; Truong VL; Wang Q; Percival MD
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4929-33. PubMed ID: 17590332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.
    Copeland RA
    Methods Biochem Anal; 2005; 46():1-265. PubMed ID: 16350889
    [No Abstract]   [Full Text] [Related]  

  • 35. Tetronic micellization, gelation and drug solubilization: Influence of pH and ionic strength.
    Alvarez-Lorenzo C; Gonzalez-Lopez J; Fernandez-Tarrio M; Sandez-Macho I; Concheiro A
    Eur J Pharm Biopharm; 2007 May; 66(2):244-52. PubMed ID: 17123799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of new synthetic scaffolds using framework libraries selected and refined via medicinal chemist synthetic expertise.
    Webb TR; Venegas RE; Wang J; Deschenes A
    J Chem Inf Model; 2008 Apr; 48(4):882-8. PubMed ID: 18335978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solubility: it's not just for physical chemists.
    Bhattachar SN; Deschenes LA; Wesley JA
    Drug Discov Today; 2006 Nov; 11(21-22):1012-8. PubMed ID: 17055411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.
    Reutzel-Edens SM
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):806-15. PubMed ID: 17117688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ionic interactions for substituted MCH1R inhibitors studied by pK(a) values.
    Lee JY; Lee H; Lim JY; Yoo SE; Kang NS
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4376-9. PubMed ID: 19497742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.